Frequency | Class of effect | Effect |
---|---|---|
Very common (≥10%) | Reproductive system and breast disorders | •
Breast tenderness
[a] • Gynecomastia [a] |
Common (1–10%) | General and psychiatric disorders | •
Asthenia • Decreased libido • Erectile dysfunction • Hot flashes |
Skin and subcutaneous tissue disorders |
• Decreased body hair | |
Hepato-biliary disorders | • Elevated liver enzymes [b] | |
Uncommon (0.1–1%) | Immune system disorders and hypersensitivity reactions | •
Angioedema • Hives |
Rare (<0.1%) or unknown | Respiratory disorders | • Lung disease [c] |
Skin and subcutaneous tissue disorders | • Sensitivity to light | |
Hepato-biliary disorders | • Liver toxicity [c] | |
|
An estimated 0.77% of the 6,480 nilutamide-treated patients, 0.04% of the 41,700 flutamide-treated patients, and 0.01% of the 86,800 bicalutamide-treated patients developed pneumonitis during the study period.
Frequency | Class of effect | Effect |
---|---|---|
Very common (≥10%) | Reproductive system and breast disorders | •
Breast tenderness
[a] • Gynecomastia [a] |
Common (1–10%) | General and psychiatric disorders | •
Asthenia • Decreased libido • Erectile dysfunction • Hot flashes |
Skin and subcutaneous tissue disorders |
• Decreased body hair | |
Hepato-biliary disorders | • Elevated liver enzymes [b] | |
Uncommon (0.1–1%) | Immune system disorders and hypersensitivity reactions | •
Angioedema • Hives |
Rare (<0.1%) or unknown | Respiratory disorders | • Lung disease [c] |
Skin and subcutaneous tissue disorders | • Sensitivity to light | |
Hepato-biliary disorders | • Liver toxicity [c] | |
|
An estimated 0.77% of the 6,480 nilutamide-treated patients, 0.04% of the 41,700 flutamide-treated patients, and 0.01% of the 86,800 bicalutamide-treated patients developed pneumonitis during the study period.